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Abstract: In this study, levels of plasma α2-Heremans-Schmid glycoprotein, serum tumor 
necrosis factor-α, serum liver function parameters and short-term mortality were measured 
in 100 hepatitis B patients. Release of interleukin-6 and tumor necrosis factor-α from the 
lipopolysaccharide-stimulated peripheral blood mononuclear cells in the presence/absence 
of  spermine  and  α2-Heremans-Schmid  glycoprotein  were  analyzed  by  enzyme-linked 
immunosorbent  assay  to  determine  the  significance  and  potential  mechanism  of  
α2-Heremans-Schmid glycoprotein in hepatitis B virus-associated liver damage. Results 
showed  that  serum  α2-Heremans-Schmid  glycoprotein  levels  in  acute-on-chronic  liver 
failure patients were significantly lower than that in chronic hepatitis B patients or healthy 
controls (p < 0.05). A negative dependence between serum human α2-Heremans-Schmid 
glycoprotein  and tumor necrosis  factor-α levels was  observed.  Interleukin-6 and tumor 
necrosis factor-α levels in the lipopolysaccharide-induced peripheral blood mononuclear 
cell  supernates  were  significantly  reduced  by  spermine  and/or  α2-Heremans-Schmid 
glycoprotein. The latter two proteins jointly inhibited cytokine release. These observations 
suggest that plasma α2-Heremans-Schmid glycoprotein is an independent marker of liver 
damage  and a prognostic indicator  of hepatitis  B virus  chronicity.  It may  reduce liver 
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inflammation  by  partially  inhibiting  release  of  inflammatory  factors  from  activated 
peripheral blood mononuclear cells. 
Keywords: human fetuin-a; α2-Heremans-Schmid glycoprotein; spermine; acute-on-chronic 
liver failure 
 
1. Introduction 
Fetuin-a is a 60 kDa glycoprotein first identified by Pederson et al. in 1944. Human fetuin-a, now 
known  as  α2-Heremans-Schmid  glycoprotein  (AHSG),  is  expressed  in  several  tissues  of  the  
embryo [1]. Although the principal source of this protein in adults are the hepatocytes [2], it is also 
expressed by monocytes or macrophages. AHSG is a natural antagonist of several growth factors, such 
as insulin, transforming growth factor-â , epidermal growth factor, lymphocyte mitogenic protein, and 
hepatocyte growth factor/scatter factor [3,4]. The main physiological functions of AHSG have been 
widely studied and demonstrated
 [5–7]. Recently, interest has been focused on the anti-inflammatory 
effect of this protein. As a negative acute-phase protein, its normal circulating level in an adult is 
significantly reduced during injury and infection. Wang et al. observed that spermine, a ubiquitous 
biogenic polyamine that accumulates at  sites  of injury or inflammation, could  inhibit macrophage 
cytokine synthesis in the presence of AHSG [8]. In addition, in vitro and in vivo data have indicated 
that  AHSG  suppresses  the  release  of  tumor  necrosis  factor  (TNF)  from  lipopolysaccharide  
(LPS)-stimulated macrophages [7]. AHSG plays a protective role in experimental sepsis by attenuating 
late mediators of lethal systemic inflammation, and protects the fetus from TNF [9,10]. 
Hepatitis B is still a major health problem. Globally, there are around 350 million people infected 
with  chronic  hepatitis  B  virus  (HBV),  75%  of  which  are  in  the  Asia-Pacific  region.  Immune 
dysfunction is the main pathogenic mechanism in the chronicity of this infection and HBV-related 
liver failure [11]. Many lines of evidence have suggested that cellular and humoral immune responses 
are required for viral clearance, and that non-HBV-specific immune response is responsible for the 
liver damage [12–14]. Recent data from animal models and humans indicate that excessive stimulation 
of the endotoxin, which is usually produced by intestinal tract bacteria in patients with hepatitis B, 
results in secondary live injury and aggravates hepatitis. 
Considering  the  anti-inflammatory  role  of  AHSG  and  the  excessive  immune  responses  in  the 
pathology of hepatitis B, we speculated that AHSG may be involved in reducing secondary hepatic 
injury by inhibiting excessive inflammation in patients with viral hepatitis and/or liver failure. Thus, 
serum indicators of liver function, such as plasma AHSG and TNF-α level in subjects with chronic 
hepatitis B and acute-on-chronic liver failure (ACLF) were examined to reveal the clinical significance 
of AHSG. To investigate the potential mechanism of this protein, we hypothesized that in the intestinal 
endotoxemia-correlated  progression  of  ACLF,  AHSG  may  partially  regulate  the  release  of 
inflammatory mediators such as TNF-α and interleukin 6 (IL-6) by inhibiting the activation of primary 
human peripheral blood mononuclear cells (PBMCs). Thus, we cultured human PBMCs and measured 
the TNF-α and IL-6 levels in vitro to investigate the potential mechanism of AHSG in inhibiting 
increased LPS-induced inflammation. Int. J. Mol. Sci. 2011, 12                       
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2. Results 
2.1. Subjects 
One hundred hospitalized patients with chronic hepatitis B (CHB) and HBV-related ACLF were 
included  in  the  present  study  (Table  1).  According  to  the  recommendations  of  the  Asian  Pacific 
Association  for  the  Study  of  the  Liver  [15],  diagnosis  of  CHB  and  ACLF  was  based  on  clinical 
manifestations and elevated values of serum alanine aminotransferase (ALT), total serum bilirubin 
(TBIL),  and  prothrombin  time  activity  (PTA)  percentage  for  at  least  one  year  after  the  initial 
determination  associated  with  positive  serum  HBV  markers  [16].  There  was  no  evidence  of  
co-infection with other hepatotropic viruses. Other possible causes of liver damage, such as alcohol, 
drugs or autoimmune diseases, and genetic liver diseases were excluded. Patients who had received 
immunomodulator therapy within three months were also excluded. As controls, 12 healthy individuals 
were recruited. The study was approved by the hospital ethics committee, and all patients and controls 
gave their consent before blood donation. 
Table 1. Clinical characteristic of the studied subjects ( X ±  SD). 
  Controls  CHB  ACLF 
Sex (M/F)  12 (8/4)  50 (37/13)  50 (38/12) 
Average Age (yr)  38.3 ±  9.5  40.3 ±  5.8  39.0 ±  6.0 
Average ALT (U/L)  21.96 ±  4.72  55.48 ±  10.60  449.21 ±  57.40 
Average TBIL (μmol/L)  8.42 ±  1.40  9.81 ±  3.64  414.08 ±  102.63 
Average A (g/L)  44.65 ±  5.39  46.03 ±  6.18  30.28 ±  4.65 
PTA (%)  93.34 ±  2.13  92.00 ±  7.39  37.60 ±  9.13 
Serum HBV-DNA (+)  0  30  50 
CHB,  chronic  hepatitis  B;  ACLF,  HBV-related  acute-on-chronic  liver  failure;  ALT,  alanine 
aminotransferase; TBIL, total serum bilirubin; A, serum albumin; PTA, prothrombin activity. 
2.2. Serum AHSG and TNF-α in Subject with CHB and ACLF 
The mean concentrations of AHSG and TNF-α in the sera of subjects with CHB and HBV-related 
ACLF are presented in Figures 1 and 2.  
Figure 1. Serum AHSG level in patients and controls. P < 0.01, serum AHSG level was 
significantly lower in ACLF patients than that in CHB patients and healthy controls. 
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Figure 2. Serum TNF- level in patients and controls. P < 0.01 Serum TNF- level was 
significantly higher in ACLF patients than in CHB patients and healthy controls. 
 
The serum AHSG level was significantly lower in ACLF patients (115.21 ±  42.28 µg/mL) than that 
in CHB patients (253.02 ±  49.56 µg/mL, P < 0.01) and healthy controls (280.33 ±  66.13 µg/mL,  
P < 0.01), respectively. However, there were no significant differences between CHB patients and the 
healthy  controls  (P  >  0.05).  The  plasma  TNF-α  level  in  ACLF  patients  (426.71  ±   91.37  pg/mL)  
was  significantly  higher  than  in  healthy  controls  (116.50  ±   18.76  pg/mL)  and  CHB  patients  
(196.22 ±  52.16 pg/mL) (P < 0.01). 
2.3. Serum AHSG Levels and Short-Term Mortality 
The fifty ACLF patients were followed up for one month. Fifteen of them died due to liver failure 
(group A); whereas the rest showed improvement in clinical and laboratory tests (group B). The serum 
AHSG levels (P < 0.05) and PTA (P < 0.01) in group B were significantly higher than those in group 
A (Table 2). However, there was no significant difference in the TBIL, serum albumin, and TNF-α 
levels (P > 0.05) between the two groups. 
Table 2. Correlation between serum AHSG levels and short-term mortality. 
Groups  n  AHSG (µg/mL)  PTA (%)  TBIL (µmol/L)  A (g/L)  TNF-α (pg/mL) 
A  15  85.26 ±  20.54
#  29.9 ± 8.22*  453.09 ± 117.98  28.53 ± 4.85  448.27 ± 100.58 
B  35  128.05 ± 36.52  40.90 ± 7.26  397.36 ± 92.13  31.03 ± 4.43  417.47 ± 87.03 
Compared with group B, *P < 0.01; 
#P < 0.05. 
2.4. Correlation Analysis 
To investigate whether plasma AHSG was associated with the circulating markers of inflammation 
and liver function in vivo, we analyzed cross-sectional data from 100 subjects, which consisted of  
50 CHB patients and 50 ACLF patients. As shown in Figure 3, a positive correlation was observed 
between the serum AHSG level and PTA or serum albumin. A negative correlation was found between 
serum AHSG and TNF-α levels or serum TBIL concentration. Int. J. Mol. Sci. 2011, 12                       
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Figure 3. Correlations between serum AHSG levels and laboratory parameters in CHB and 
ACLF patients. (A) TNF-; (B) TB1IL; (C) Albumin; (D) PTA. P < 0.01 serum ANSG 
level  was  positively  correlated  with  PTA  or  serum  albumin  level,  while  negatively 
correlated  with  serum  TNF-  level  or  TBIL  concentration  in  both  CHB  and  
ACLF patients. 
 
2.5. Effects of AHSG on Cytokine Production in LPS-Stimulated PBMCs 
Cells were cultured in seven groups. Culture media were collected after 24 h and assayed for TNF-α 
and IL-6. The results are illustrated in Table 3. Cultures exposed to LPS alone resulted in a significant 
increase in the TNF-α level from 6.44 ±  3.88 (group 1) to 423.73 ±  97.66 pg/mL (group 2) (P < 0.01), 
and in the IL-6 level from 19.21 ±  5.59 (group 1) to 584.73 ±  82.36 pg/mL (group 2) (P < 0.01). 
However,  addition  of  spermine  (group  3)  significantly  reduced  the  TNF-α  and  IL-6  levels  to  
72.97  ±   18.32  and  239.96  ±   48.26  pg/mL,  respectively  (P  <  0.01).  Substantial  decreases  in  the  
TNF-α and IL-6 levels were observed when AHSG and spermine were added simultaneously (group 4) 
(P < 0.05).  
To antagonize the effect of endogenous AHSG on the PBMCs, an AHSG-specific antibody was 
administered to the LPS-stimulated PBMCs in the presence of spermine (group 5). The TNF-α and  
IL-6 levels in group 5 increased to 261.43 ±  54.07 and 555.42 ±  69.78 pg/mL, respectively, which was 
significantly higher than those in groups 3 or 4 (P < 0.01). However, the level of TNF-α in group 5 Int. J. Mol. Sci. 2011, 12                       
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was still significantly lower than  that in the  LPS-stimulated group (group 2,  P < 0.01), while no 
significant difference of IL-6 level was observed between group 5 and group 2 (P > 0.05). 
Serum  albumin  was  chosen  as  a  protein  control  to  investigate  the  specificity  of  the  
anti-inflammatory  effect  of  AHSG.  The  addition  of  albumin  (group  6)  significantly  decreased  the  
TNF-α  or  IL-6  levels.  On  the  other  hand,  exposure  to  AHSG  alone  produced  approximately  
258.55 ±  54.87 pg/mL of TNF-α and 503.78 ±  90.87 pg/mL of IL-6 after 24 h, which were significantly 
lower than those in group 2 (P < 0.05). However, no significant difference was observed in TNF-α or 
IL-6 levels in groups 5, 6, and 7 (P > 0.05). Thus, the production of TNF-α and IL-6 byLPS-stimulated 
human PBMC could be reduced by a given dose of AHSG and spermine. 
Table 3. Effects of AHSG on PBMC TNF-α and IL-6 levels. 
Group 
Supernatant TNF-α levels 
(pg/mL) 
Supernatant IL-6 levels 
(pg/mL) 
1  PBMC  6.44 ±  3.88  19.21 ±  5.59 
2  PBMC + LPS  423.73 ±  97.66*  584.73 ±  82.36& 
3  PBMC + LPS + spermine  72.97 ±  18.32**  239.96 ±  48.26** 
4  PBMC + LPS + spermine + AHSG  25.11 ±  5.61***  114.90 ±  30.83*** 
5  PBMC + LPS + spermine + AHSG 
antibody 
261.43 ±  54.07
#  555.42 ±  69.78
@ 
6  PBMC + LPS + albumin  223.92 ±  46.65
##  403.46 ±  78.80
## 
7  PBMC + LPS + AHSG   258.55 ±  54.87
###  503.78 ±  90.87
### 
*P < 0.01, versus groups 1, 3, 4, 5, 6 and 7; **P < 0.05, versus groups 1, 2, 4, 5 and 6; ***P < 0.01, 
versus groups 2, 3, 5 and 6; 
#P < 0.01, versus groups 1, 2, 3 and 4; 
##P < 0.05, versus groups 1, 2, 3 
and 4; 
###P < 0.05, versus groups 1, 2, 3, and 4; & P < 0.01, versus groups 1, 3, 4, 6; @ P < 0.05, 
versus groups 1, 3 and 4. 
3. Discussion 
AHSG,  a  member  of  the  cystatin  super  family  [1],  is  involved  in  various  conditions  such  as 
metabolic disease, tumor, and sepsis [17,18]. Variations of this protein have been confirmed in patients 
with liver diseases [19–21]. Low serum AHSG levels are observed in patients with alcoholic hepatitis, 
acute  drug-induced  hepatitis,  and  chronic  autoimmune  hepatitis,  as  well  as  in  fatty  liver,  primary 
biliary cirrhosis, and hepatocellular cancer patients. After long-term (up to 1 year) follow up, Kalabay 
et al. concluded that the sensitivity, specificity, and predictive values of serum AHSG concentration 
exceeded the scores from the model for end-stage liver disease. However, the potential role of AHSG 
in patients with viral hepatitis remains unknown. Our present study demonstrated a significant decline 
in the serum AHSG levels in ACLF patients compared with those in CHB patients or healthy controls. 
Further analysis showed a negative correlation between the AHSG and serum TNF-α level. Analysis of 
the relationship between the serum AHSG levels and short-term mortality showed that serum AHSG 
level was significantly higher in the surviving patients compared with those who succumbed to their 
illness;  this  reveals  that  low  serum  AHSG  may  be  responsible  for  poor  prognosis.  A  positive 
correlation of the serum AHSG level with conventional liver function indicators (PTA and serum 
albumin levels) and a negative correlation with TBIL concentration were observed. These findings 
indicate that the serum AHSG level was directly linked to the severity of liver damage. Hence, serum Int. J. Mol. Sci. 2011, 12                       
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AHSG level is a new independent marker of liver damage in chronic HBV-infected patients. AHSG 
may reduce excessive liver inflammation and cell necrosis by inhibiting the TNF-α expression. The 
reduction  of  serum  AHSG  level  in  viral  hepatitis  may  be  explained  by  the  following:  First,  the 
synthesis of AHSG is reduced significantly due to the large number of liver cells undergoing apoptosis 
or necrosis, and concomitant loss of function of residual liver cells. Second, substantial amounts of 
AHSG may be consumed in the inhibition of increased expression of cytokines (such as TNF-α) during 
liver failure. These hypotheses need to be proved by further studies. 
Besides, significantly lower serum AHSG level in deceased ACLF patients was observed than in 
survived patients, while no significant differences in serum TNF-, TBIL and albumin levels were 
observed between the two groups. However, negative correlations between serum AHSG level and 
TNF-/TBIL/albumin level in ACLF patients  were observed during further analysis. The possible 
reasons  for the discrepancy  were as  follows: (i) the correlation  coefficients  were not  big enough. 
Correlation  coefficients  between  serum  AHSG  and  TNF-/TBIL/albumin  levels  were  (−0.622,  
P  <  0.05),  (−0.560,  P  <  0.05)  and  (0.572,  P  <  0.05),  respectively.  Therefore,  apparent  statistical 
differences haven’t been observed; (ii) the comparatively small sample size (subjects of ACLF = 50, 
survived patients = 35, deceased ACLF patients = 15) might be another reason. 
Hepatic  and  circulating  inflammatory  cytokines  play  a  critical  role  in  the  pathophysiology  of  
ACLF [22]; the importance of intestinal endotoxin in this process has drawn more attention [23]. The 
present study suggests that the LPS-macrophage activation-TNF-α-axis [24] is the core of secondary 
liver injury leading to liver failure. TNF-α and IL-6 are considered critical inflammatory cytokines in 
immunopathogenesis. Although various agents can cause hepatocyte injury and liver failure, many 
studies  in  patients  and  animal  models  have  strongly  suggested  that  TNF-α  and  IL-6,  the  major 
mediators of the acute-phase response, are involved in the induction of apoptosis and in triggering liver 
damage, which ultimately lead to  hepatic failure  [25]. Therefore, the removal of proinflammatory 
cytokines from the plasma might be help to alleviate this condition [26]. Thus, we targeted TNF-α and 
IL-6 to reveal the potential mechanism by which AHSG may be involved in the pathophysiology of 
HBV-related ACLF. Our in vitro investigation showed that the levels of these cytokines increased 
significantly in the LPS-stimulated PBMCs, which was consistent with previous studies [27,28]. In 
contrast,  the  IL-6  and  TNF-α  levels  were  significantly  reduced  when  spermine  was  added;  this 
indicates  that  spermine  inhibited  the  release  of  these  inflammatory  mediators  in  the  presence  of 
endogenous AHSG. We also found that AHSG had a synergistic effect on inhibiting the release of 
TNF-α  and  IL-6  when  added  with  spermine.  A  combination  of  exogenous  spermine  and  AHSG 
maximally reduced the release of the inflammatory mediators.  
When an AHSG antibody was added to antagonize the effect of endogenous AHSG, significant 
increases in the TNF-α and IL-6 levels were observed, revealing that the AHSG antibody antagonized 
not  only  the  contribution  of  endogenous  AHSG  on  the  surface  of  the  PBMCs,  but  also  the  
anti-inflammatory effect of spermine.This behavior confirmed that AHSG was essential for spermine. 
The  same  result  has  been  obtained  in  previous  studies  wherein  AHSG  alone  administered  at  low 
concentrations did not suppress the release of inflammatory mediators. However, AHSG itself could 
also suppress the release of many inflammatory mediators such as nitric oxide and HMGB1 [29] when 
administered at high concentrations.  Int. J. Mol. Sci. 2011, 12                       
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Thus,  we  consider  that  in  the  process  leading  to  its  anti-inflammatory  effect,  AHSG  plays  a 
protective role by attenuating the release of pro-inflammatory mediators. In addition, serum albumin, a 
negative acute-phase protein and an inflammatory marker, which has the similar molecular weight and 
is  also  synthesized in  the liver, was  chosen as the control.  Albumin suppressed the inflammatory 
response to some extent. Although the mechanism for this process remains ambiguous, it may be 
related to: (1) the change in the protein proportion in the media which favors cell proliferation in the 
presence of albumin; (2) a potential anti-inflammatory role of albumin, which needs to be proved; and 
(3) in the presence of albumin the concentration of free LPS is reduced due to its binding to albumin. 
This would directly result in the decreased stimulating ability of LPS.  
In summary, low serum AHSG level and intestinal endotoxemia are critical pathological states in 
subjects of liver failure, while the peripheral blood mononuclear cells and inflammatory factors such as 
TNF-α and IL-6 are important immune targets in the pathological process of liver failure. Focusing on 
the in vivo situations above, we studied the effect of administrated AHSG on the LPS stimulated 
release of inflammatory factors from PBMCs in vitro. The results above indicated that certain dose of 
AHSG attenuated the release of TNF-α and IL-6 from LPS stimulated PBMCs. Hence, we consider 
that there may be a vicious cycle in the pathologic progression of chronic severe hepatitis, especially 
ACLF. The synthesis of AHSG is reduced significantly because of liver damage and cell necrosis, 
which results in a reduction of the anti-inflammatory effect of circulating AHSG. Thus, the hepatic and 
circulating inflammatory cytokines are produced in large amounts and mediate further damage to the 
liver. Therefore, administration of exogenous AHSG may be beneficial to reconstitute liver function. 
The present study revealed the potential role and preliminary data on the mechanism of AHSG in 
HBV-associated liver failure. The study had limitations in the sample size; therefore, further studies 
should be designed to clarify the specific mechanisms. 
4. Materials and Methods 
4.1. Determination of Serum AHSG and TNF-α Concentration 
Blood samples were collected from patients with empty stomachs in luce prima. Enzyme-linked 
immunosorbent assay (ELISA) for serum levels of AHSG (Bio Vendor RD191037100, Brno, Czech 
Republic)  and  TNF-α  (Abazyme  EL10019,  Shanghai,  China)  were  performed  according  to 
manufacturer instructions. 
4.2. Preparation and Culture of PBMCs 
PBMCs (10 mL, ~1 ×  10
6 cell/mL; 3 replicates) were isolated from the peripheral blood of an adult 
male healthy donor by Ficoll-Hypaque density gradient centrifugation (once a week for three weeks, 
three replicates for every time). Around 1 ×  10
6 cells/mL were suspended in RPMI 1640 (Gibco, 
Grand Island, NY, USA) culture medium supplemented with 10% heat-inactivated fetal calf serum 
(Gibco,  Bethesda,  MD,  USA),  100  U/mL  penicillin,  and  100  mg/mL  streptomycin  (Huamei  Co., 
Shanghai, China). Cell viability was determined by trypan blue exclusion (>95% viable). 
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4.3. Cell Culture and Cytokine ELISA 
PBMCs (1 ×  10
6 cell/mL) were cultured in 24-well polystyrene plates (Costar, Newark, NJ, USA) at 
37 ° C in the presence of 5% CO2 for 4 h. Each well was additionally supplemented with 1.0 mL of the 
complete  medium  containing  one  or  a  combination  of  the  following:  50  µg/mL  fetuin-a  
(Sigma-Aldrich Co., St. Louis, MO, USA), 50 μmol/L spermine (Sigma-Aldrich Co., St. Louis, MO, 
USA), and 50 µg/mL AHSG antibody (Abcam, San Francisco, CA, USA) (Table 4). Some wells were 
instead  supplemented  with  sterile  bovine  serum  albumin  (Gibco,  Grand  Island,  NY,  USA).  A  
100 ng/mL standard dose of LPS (Sigma-Aldrich Co., St. Louis, MO, USA) was added to the wells, 
which were used for experiments on LPS stimulation. After 24 h incubation under 5% CO2 at 37 ° C, 
the culture media were collected, and the TNF-α and IL-6 levels were measured by ELISA (SUNBIO 
HE001, SUNBIO HE003, Beijing, China) according to the instructions of the manufacturer. 
4.4. Statistical Analysis 
All data were analyzed using SPSS 11.5 software and were summarized as means and standard 
deviations. The hypothesis was tested using least-significant-difference t-test, and linear correlation 
analysis was used between two sets of data. ANOVA analysis was used for the comparison of different 
groups. For all tests, a two-sided probability (P < 0.05) was considered statistically significant.  
5. Conclusions 
Serum AHSG could be considered as a new independent marker of liver damage in chronic viral 
hepatitis, especially ACLF. Increased administration of AHSG may be beneficial in reducing liver 
damage, an effect which is worthy of further study. 
Acknowledgments 
The authors thank Haichao Wang from the North Shore University Hospital-New York University 
School of Medicine for providing AHSG and for his valuable suggestions.  
References 
1.  Dziegielewska,  K.M.;  Mø llgå rd,  K.;  Reynolds,  M.L.;  Saunders,  N.R.  A  fetuin-related 
glycoprotein (alpha 2HS) in human embryonic and fetal development. Cell Tissue Res. 1987, 248, 
33–41. 
2.  Triffitt,  J.T.;  Gebauer,  U.;  Ashton,  B.A.;  Owen,  M.E.;  Reynolds,  J.J.  Origin  of  plasma  
alpha2HS-glycoprotein and its accumulation in bone. Nature 1976, 262, 226–236. 
3.  Ohnishi, T.; Nakamura, O.; Arakaki, N.; Daikuhara, Y. Effect of phosphorylated rat fetuin on the 
growth of hepatocytes in primary culture in the presence  of human hepatocyte-growth factor. 
Evidence that phosphorylated fetuin is a natural modulator of hepatocyte-growth factor. Eur. J. 
Biochem. 1997, 243, 753–761. Int. J. Mol. Sci. 2011, 12                       
 
 
3855 
4.  Szweras,  M.;  Liu,  D.;  Partridge,  E.A.;  Pawling,  J.;  Sukhu,  B.;  Clokie,  C.;  Jahnen,  D.W.; 
Tenenbaum, H.C.; Swallow, C.J.; Grynpas, M.D.; Dennis, J.W. Alpha 2-HS glycoprotein/fetuin, a 
transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone 
growth and remodeling. J. Biol. Chem. 2002, 277, 19991–19997.  
5.  Komaba, H.; Fukagawa, M.  Fetuin-mineral  complex:  A new potential biomarker for vascular 
calcification? Kidney Int. 2009, 75, 874–876. 
6.  Wang, H.C.; Li, W.; Zhu, S,; Li, J.; Amore, J.; Ward, M.F.; Yang, H.; Wu, R.; Jahnen, D.W.; 
Tracey, K.J.; Wang, P.; Sama, A.E. Peripheral administration of fetuin-A attenuates early cerebral 
ischemic injury in rats. J. Cerebr. Blood Flow Metab. 2010, 30, 493–504. 
7.  Ombrellino, M.; Wang, H.; Yang, H.; Zhang, M.; Vishnubhakat, J.; Frazier, A.; Scher, L.A.; 
Friedman, S.G.; Tracey, K.J. Fetuin, a negative acute phase protein, attenuates TNF synthesis and 
the innate inflammatory response to carrageenan. Shock 2001, 15, 181–185.  
8.  Zhang, M.; Caragine, T.; Wang, H.; Cohen, P.S.; Botchkina, G.; Soda, K.; Bianchi, M.; Ulrich, P.; 
Cerami, A.; Sherry, B.; Tracey, K.J. Spermine inhibits proinflammatory cytokine synthesis in 
human mononuclear cells: A counterregulatory mechanism that restrains the immune response.  
J. Exp. Med. 1997, 185, 1759–1768. 
9.  Wang, H.; Li, W.; Zhu, S.; Li, J. Fetuin protects mice against lethal sepsis by modulating bacterial 
endotoxin-induced hmgb1 release and autophagy. Shock 2010, 33, 6–7. 
10.  Wang, H.; Zhang, M.H.; Kuniyasu, S.; Andrew, S.; Kevin, J.T. Fetuin protects the fetus from 
TNF. Lancet 1997, 350, 861–862. 
11.  Liu, Q. Role of cytokines in the pathophysiology of acute-on-chronic liver failure. Blood Purif. 
2009, 28 , 331–341. 
12.  Koziel, M.J. The immunopathogenesis of HBV infection. Antivir. Ther. 1998, 3, 13–24. 
13.  Chisari, F.V.; Ferrari, C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 1995, 13, 
29–60. 
14.  Zhang, J.Y.; Zhang, Z.; Lin, F.; Zou, Z.S.; Xu, R.N.; Jin, L.; Fu, J.L.; Shi, F.; Shi, M,; Wang, 
H.F.; Wang, F.S. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage 
in patients with chronic hepatitis B. Hepatology 2010, 51, 81–91. 
15.  Sarin, S.K.; Kumar, A.; Almeida, J.A.; Chawla, Y.K.; Fan, S.T.; Garg, H.; Silva, H.J.; Hamid, 
S.S.; Jalan, R.; Komolmit, P.; et al. Acute-on-chronic liver failure: Consensus recommendations 
of  the  Asian  Pacific  Association  for  the  study  of  the  liver  (APASL).  Hepatol.  Int.  2009,  3,  
269–282.  
16.  Papatheodoridis, G.V.; Manolakopoulos, S. EASL clinical practice guidelines on the management 
of chronic hepatitis B: The need for liver biopsy. J. Hepatol. 2009, 51 , 226–237. 
17.  Ix, J.H.; Sharma, K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: 
The roles of fetuin-A, adiponectin, and AMPK. J. Am. Soc. Nephrol. 2010, 21 , 406–412. 
18.  Sari, I.; Kebapcilar, L.; Taylan, A.; Bilgir, O.; Kozaci, D.L.; Yildiz, Y.; Yuksel, A. Fetuin-A and 
interleukin-18 levels in ankylosing spondylitis. Int. J. Rheum. Dis. 2010, 13, 75–81. 
19.  Kalabay, L.; Jakab, L.; Prohá szka, Z.; Fü st, G.; Benkö , Z.; Telegdy, L.; Lö rincz, Z.; Zá vodszky, 
P.; Arnaud, P.; Fekete, B. Human fetuin/alpha 2HS-glycoprotein level as a novel indicator of liver 
cell function and short-term mortality in patients with liver cirrhosis and liver cancer. Eur. J. 
Gastroenterol. Hepatol. 2002, 14 , 389–394. Int. J. Mol. Sci. 2011, 12                       
 
 
3856 
20.  Kalabay, L.; Gráf, L.; Vörös, K.; Jakab, L.; Benkő, Z.; Telegdy, L.; Fekete, B.; Prohászka, Z.; 
George,  F. Human serum  fetuin A/alpha 2HS-glycoprotein  level  is  associated with  long-term 
survival in patients with alcoholic liver cirrhosis, comparison with the Child-Pugh and MELD 
scores. BMC Gastroenterol. 2007, 6, 7–14. 
21.  Yilmaz, Y.; Yonal, O.; Kurt, R.; Ari, F.; Oral, A.Y.; Celikel, C.A.; Korkmaz, S.; Ulukaya, E.; 
Ozdogan, O.; Imeryuz, N.; Avsar, E.; Kalayci, C. Serum fetuin A/alpha2HS-glycoprotein levels in 
patients with non-alcoholic fatty liver disease: Relation with liver fibrosis. Ann. Clin. Biochem. 
2010, 47, 549–553.  
22.  Liu, Q. Role of cytokines in the pathophysiology of acute-on-chronic liver failure. Blood Purif. 
2009, 28, 331–341. 
23.  Yuan, G.J.; Gong, Z.J.; Zhou, X.R.; Zhang, Q.P.; Sun, X.M.; Li, X. Epigallocatechin-3-gallate 
ameliorates alcohol-induced liver injury in rats. Int. J. Mol. Sci. 2006, 7, 204–219. 
24.  Liguori, M.J.; Ditewig, A.C.; Maddox, J.F.; Luyendyk, J.P.; Lehman-McKeeman, L.D.; Nelson,  
M.; Bhaskaran, V.M.; Waring, J.F.; Ganey, P.E.; Roth, R.A.; Blomme, E.A. Comparison of TNF 
alpha to lipopolysaccharide as an inflammagen to characterize the idiosyncratic hepatotoxicity 
potential of drugs: Trovafloxacin as an example. Int. J. Mol. Sci. 2010, 11, 4697–4714.  
25.  Sen, S.; Davies, N.A.; Mookerjee, R.P.; Cheshire, L.M.; Hodges, S.J.; Williams, R.; Jalan, R. 
Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: A randomized 
controlled study. Liver Transpl. 2004, 10, 1109–1119.  
26.  Ambrosino, G.; Naso, A.; Feltracco, P.; Carraro, P.; Basso, S.M.; Varotto, S.; Cillo, U.; Zanus, G.; 
Boccagni,  P.;  Brolese,  A.;  Plebani,  M.;  Giron,  G.;  Amico,  D.F.  Cytokines  and  liver  failure: 
Modification of TNF- and IL-6 in patients with acute on chronic liver decompensation treated 
with Molecular Adsorbent Recycling System (MARS). Acta Biomed. 2003, 74, 7–9. 
27.  Wang, J.H.; Redmond, H.P.; Watson, R.W.; Bouchier, H.D. Role of lipopolysaccharide and tumor 
necrosis factor-alpha in induction of hepatocyte necrosis. Am. J. Physiol. 1995, 269, 297–304. 
28.  Shah, V.O.; Ferguson, J.E.; Hunsaker, L.A.; Deck, L.M.; Vander, D.L. Natural products inhibit 
LPS-induced  activation  of  pro-inflammatory  cytokines  in  peripheral  blood  mononuclear  cells. 
Nat. Prod. Res. 2010, 24 , 1177–1188. 
29.  Li,  W.;  Zhu,  S.;  Li,  J.;  Huang,  Y.;  Zhou,  R.;  Fan,  X.;  Yang,  H.;  Gong,  X.;  Eissa,  N.T.;  
Jahnen,  D.W.;  Wang,  P.;  Tracey,  K.J.;  Sama,  A.E.;  Wang,  H.  A  hepatic  protein,  fetuin-A, 
occupies a protective role in lethal systemic inflammation. Plos One 2011, 6 , e16945. 
© 2011  by the authors; licensee  MDPI,  Basel, Switzerland. This  article is  an open  access article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 
 